Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
PresentationPatrick TrucchioH.C. Wainwright & Co, LLC, Research Division Okay. Good morning, everyone. Welcome back to H.C. Wainwright's 27th Annual Global Investment Conference held on September 8 to 10, 2025. My name is Patrick Trucchio, senior health care analyst at H.C. Wainwright. It's my pleasure to introduce you to our next company. It's Precision BioSciences, a clinical stage gene editing company, leveraging its novel and proprietary ARCUS platform, developed in vivo gene editing therapies for disea ...